Amid accusations of manipulating data associated with trials for its Alzheimer’s drug candidate simufilam, Cassava Sciences had a bit of good news when the FDA denied a citizen petition pressing the agency to investigate claims that Cassava changed trial data.
Source: Drug Industry Daily